Hetal K Patel
Biographic Data
| ID | 9064779 |
|---|---|
| NAME | Hetal K Patel |
| GIVEN NAMES | Hetal K |
| FAMILY NAME | Patel |
| SIGNATURE | PATEL H K |
| AFFILIATIONS | Centers for Disease Control and Prevention |
| ORCID | 0000-0002-5468-2591 |
| VERIFIED | Yes |
| TOTAL WORKS | 6 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 6 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2022 |
| LATEST PUBLICATION YEAR | 2025 |
| H-INDEX | 0 |
Field validation and application of the luminex triplex HIV assay to estimate HIV prevalence and HIV-1 incidence in Nigeria
HIV cross-sectional surveys require multi-layered testing with several tests to estimate HIV prevalence and HIV-1 incidence. We evaluated the performance and accuracy of the newly developed HIV Triplex assay to diagnose HIV-1 and HIV-2 and detect HIV-1 recent infections using plasma samples from the 2018 Nigeria AIDS Indicator and Impact Survey (NAIIS). Plasma samples from consenting HIV-positive (n=2,773) and a subset of HIV-negative samples (n=…
HIV risk behaviour, viraemia, and transmission across HIV cascade stages including low-level viremia
As antiretroviral treatment (ART) coverage for people living with HIV (PLHIV) increases, HIV programmes require up-to-date information about evolving HIV risk behaviour and transmission risk, including those with low-level viremia (LLV; >50 to ≤1000 copies/mL), to guide prevention priorities. We aimed to assess differences in sexual risk behaviours, distribution of viral load (VL) and proportion of transmission across PLHIV subgroups. We analysed…
Performance evaluation of the Asante Rapid Recency Assay for verification of HIV diagnosis and detection of recent HIV-1 infections
We previously described development of a rapid test for recent infection (RTRI) that can diagnose HIV infection and detect HIV-1 recent infections in a single device. This technology was transferred to a commercial partner as Asante Rapid Recency Assay (ARRA). We evaluated performance of the ARRA kits in the laboratory using a well-characterized panel of specimens. The plasma specimen panel (N = 1500) included HIV-1 (N = 570), HIV-2 (N = 10), and…
Prevalence of and factors associated with late diagnosis of HIV in Malawi, Zambia, and Zimbabwe
Introduction Late diagnosis of HIV (LD) increases the risk of morbidity, mortality, and HIV transmission. We used nationally representative data from population-based HIV impact assessment (PHIA) surveys in Malawi, Zambia, and Zimbabwe (2015–2016) to characterize adults at risk of LD and to examine associations between LD and presumed HIV transmission to cohabiting sexual partners. Methods We estimated the prevalence of LD, defined as CD4 count R…
Performance of HIV rapid testing algorithm in Nigeria
Background The Nigeria AIDS Indicator and Impact Survey (NAIIS), a cross-sectional household survey, was conducted in 2018 with primary objectives to estimate HIV prevalence, HIV-1 incidence, and status of UNAIDS 90-90-90 cascade. We conducted retrospective analysis of the performance of HIV rapid tests and the national HIV testing algorithm used in Nigeria. Methods The national algorithm included Determine HIV-1/2 as test 1 (T1), Unigold HIV-1/2…
Assessment of suitability of saxagliptin hydrochloride for development of controlled release parenteral formulation by preformulation studies
The main objective of pre-formulation study is to develop the stable, elegant, safe and effective drug delivery system by establishing drug kinetic profile, formulation compatibility with different excipients and physico-chemical parameters of new drug molecules. This could provide key evidence for implementing formulation design or requirement of the molecular alteration. So, in the present study preformulation studies were performed on Saxaglip…
No prominent works on this page.
Performance evaluation of the Asante Rapid Recency Assay for verification of HIV diagnosis and detection of recent HIV-1 infections
We previously described development of a rapid test for recent infection (RTRI) that can diagnose HIV infection and detect HIV-1 recent infections in a single device. This technology was transferred to a commercial partner as Asante Rapid Recency Assay (ARRA). We evaluated performance of the ARRA kits in the laboratory using a well-characterized panel of specimens. The plasma specimen panel (N = 1500) included HIV-1 (N = 570), HIV-2 (N = 10), and…
Prevalence of and factors associated with late diagnosis of HIV in Malawi, Zambia, and Zimbabwe
Introduction Late diagnosis of HIV (LD) increases the risk of morbidity, mortality, and HIV transmission. We used nationally representative data from population-based HIV impact assessment (PHIA) surveys in Malawi, Zambia, and Zimbabwe (2015–2016) to characterize adults at risk of LD and to examine associations between LD and presumed HIV transmission to cohabiting sexual partners. Methods We estimated the prevalence of LD, defined as CD4 count R…
Performance of HIV rapid testing algorithm in Nigeria
Background The Nigeria AIDS Indicator and Impact Survey (NAIIS), a cross-sectional household survey, was conducted in 2018 with primary objectives to estimate HIV prevalence, HIV-1 incidence, and status of UNAIDS 90-90-90 cascade. We conducted retrospective analysis of the performance of HIV rapid tests and the national HIV testing algorithm used in Nigeria. Methods The national algorithm included Determine HIV-1/2 as test 1 (T1), Unigold HIV-1/2…
Assessment of suitability of saxagliptin hydrochloride for development of controlled release parenteral formulation by preformulation studies
The main objective of pre-formulation study is to develop the stable, elegant, safe and effective drug delivery system by establishing drug kinetic profile, formulation compatibility with different excipients and physico-chemical parameters of new drug molecules. This could provide key evidence for implementing formulation design or requirement of the molecular alteration. So, in the present study preformulation studies were performed on Saxaglip…
HIV risk behaviour, viraemia, and transmission across HIV cascade stages including low-level viremia
As antiretroviral treatment (ART) coverage for people living with HIV (PLHIV) increases, HIV programmes require up-to-date information about evolving HIV risk behaviour and transmission risk, including those with low-level viremia (LLV; >50 to ≤1000 copies/mL), to guide prevention priorities. We aimed to assess differences in sexual risk behaviours, distribution of viral load (VL) and proportion of transmission across PLHIV subgroups. We analysed…
Field validation and application of the luminex triplex HIV assay to estimate HIV prevalence and HIV-1 incidence in Nigeria
HIV cross-sectional surveys require multi-layered testing with several tests to estimate HIV prevalence and HIV-1 incidence. We evaluated the performance and accuracy of the newly developed HIV Triplex assay to diagnose HIV-1 and HIV-2 and detect HIV-1 recent infections using plasma samples from the 2018 Nigeria AIDS Indicator and Impact Survey (NAIIS). Plasma samples from consenting HIV-positive (n=2,773) and a subset of HIV-negative samples (n=…
Medicine (6 works) · HIV Research and Treatment (5 works) · HIV/AIDS Research and Interventions (5 works) · Immunology (4 works) · Internal Medicine (4 works) · Population (4 works) · Environmental health (3 works) · HIV screening (3 works) · Men who have sex with men (3 works) · Antibody (2 works)